Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-04

Clinical Trial Update: Ixazomib Maintenance Study in Patients With AL Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ixazomib as maintenance therapy for AL amyloidosis, with the trial currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NINLARO (ixazomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: AL Amyloidosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING